To access the Live Streaming Sessons, CME Surveys and other symposium materials please login using your registration email address.



CME Certificates will be issued digitally after Speaker Evaluations and Overall Surveys are completed. Surveys are accessible from this website after logging in with the email address you submitted during registration. Surveys will be available online starting the first day of the symposium. You must complete the process by March 4, 2024 in order to receive your certificate. Certificates will be available online until August 1 and are printable directly from the website.


The AAFP has reviewed 24th Annual San Diego Heart Failure Symposium for Primary Care & Internal Medicine Physicians and deemed it acceptable for up to 10.25 Live AAFP Prescribed credits. Term of Approval is from 02/09/2024 to 02/10/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.


The 24th Annual San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians! This year’s meeting will provide a comprehensive overview of contemporary management strategies for patients with heart failure. The talks, panel discussions and case presentations will focus on best practices and recent guideline recommendations as interpreted by a faculty that is made up of leaders in the field. Over the two day course, we will review the full range of management options for patients throughout the spectrum of heart failure, starting with Stage A patients who are identified by the presence of risk factors for cardiovascular disease and extending to those with changes in cardiac structure and function but who remain asymptomatic (Stage B). Additional sessions will provide in depth discussion of the management of symptomatic Stage C patients with HFpEF and HFrEF and the treatment options that are available for patients with Stage D or end-stage heart failure. New approaches for diagnosing heart failure and identifying specific groups of patients that require special management considerations (such as amyloid, hypertrophic and genetic cardiomyopathies) will be highlighted as will strategies for successful implementation of guideline directed therapies. Faculty members will discuss the role of drugs, devices and surgical interventions with a focus on the most effective treatment approaches and share their experience in how to best implement them.

The Symposium combines didactic talks with panel discussions and case presentations to provide a full and balanced perspective of relevant management issues. An addition to the Symposium this year is the input that will be offered by patients who will provide their own unique insights on the various treatment options that are available. Also new to the Symposium are the Coffee with the Faculty and ‘Fascinoma’ sessions that will be held on Friday and Saturday mornings, respectively. These sessions are designed specifically to allow the audience an opportunity to interact with the faculty in a relaxed informal setting while getting the insight of experts in the field on management issues and challenging cases. Our goal, as always, is to provide cutting edge information in a format that will enhance adaption of the knowledge that is gained into clinical practice.


This course is designed for cardiologists, internists, primary care physicians, nurses, PA’s, PharmD’s and all other allied healthcare professionals with an interest in heart failure.


At the conclusion of this activity, participants should be able to:

  1. Summarize current and emerging treatments available for preventing and treating heart failure and provide information to help in the selection of the most effective choices in individual patients.
  2. Review strategies for implementing medical and device therapies that will lead to improved outcomes in heart failure patients.
  3. Define how specific populations including minorities, women and the elderly respond to various approaches to treating risk factors and heart failure.


Over five million Americans (two percent of the U.S.) are living with heart failure (HF). An estimated 670,000 new cases of HF are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the U.S. HF is common, but unrecognized and often misdiagnosed. Recent data have shown that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010:16; 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585).

Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S. on average, patients with heart failure received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010).

Despite important advances in treatment, patients with HF continue to experience unacceptably high rates of morbidity and mortality. This along with the enormous cost of caring for a growing number of HF patients has resulted in increased scrutiny of existing and emerging therapies.


It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.